Fox Run Management’s Stoke Therapeutics STOK Stock Holding History

Fox Run Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,780	Closed	-$91.6K	–	1218
2025 Q1	$91.6K	Buy	+13,780	New	+$128K	0.01%	862

Other funds holding STOK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fox Run Management's STOK Position: Q2 2025 in Review

Fox Run Management sold out of Stoke Therapeutics (STOK) in Q2 2025, closing a stake of 13,780 shares — an estimated $91.6K sold.

Fox Run Management first reported a position in STOK in Q1 2025 and held it in 1 quarter. The position peaked at $91.6K in Q1 2025. 133 funds tracked by Wall St. Rank hold STOK as of Q2 2025.

Fox Run Management reported no remaining Stoke Therapeutics position as of Q2 2025 after selling out during the quarter.
Fox Run Management sold 13,780 Stoke Therapeutics shares in Q2 2025, an estimated $91.6K.
Fox Run Management first reported a position in Stoke Therapeutics in Q1 2025 and held it in 1 quarter.
Fox Run Management's Stoke Therapeutics position peaked at $91.6K in Q1 2025.
133 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2025.

Based on Fox Run Management's 13F filing for Q2 2025, filed 6 Aug 2025.